Status:

COMPLETED

Presepsin as a Predictor for Postoperative Complications Following Pancreatic Resection

Lead Sponsor:

Medical University Innsbruck

Conditions:

Postoperative Complications

Eligibility:

All Genders

18+ years

Phase:

NA

Brief Summary

The study investigates the local and systemic inflammatory response following pancreatic resections.

Detailed Description

Pancreatic resections (PR) are major hepato-pancreatico-biliary (HPB) surgeries associated with significant morbidity and mortality. Despite improvements in surgical technique, as well as peri- and po...

Eligibility Criteria

Inclusion

  • Patients with any pancreatic pathology (benign and malign) requiring surgery
  • Written informed consent
  • \>= 18 years

Exclusion

  • Pregnancy
  • Patients who are not capable of giving informed consent (e.g. with existing medical trustee)

Key Trial Info

Start Date :

July 11 2017

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

December 31 2019

Estimated Enrollment :

86 Patients enrolled

Trial Details

Trial ID

NCT04294797

Start Date

July 11 2017

End Date

December 31 2019

Last Update

March 4 2020

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Medical University of Innsbruck

Innsbruck, Tyrol, Austria, 6020

Presepsin as a Predictor for Postoperative Complications Following Pancreatic Resection | DecenTrialz